The National Institutes of Health on Monday named John H. Powers III permanent director of the National Institute of Allergy and Infectious Diseases, handing the job to the physician who had run the institute on an acting basis since June and ending a leadership vacancy that dated to March 2025.
NIH Director Jay Bhattacharya paired the appointment with a blunt statement of direction. "No more dangerous gain of function will happen under John's leadership," he told the New York Post in an interview on Friday, adding that the institute would not conduct what he called "mad science experiments." He described NIAID as "now purely a civilian agency" and said its research portfolio is being rebalanced toward the infectious diseases that most commonly affect Americans.
The change reaches deep into the institute's finances. As recently as fiscal 2025, roughly a third of NIAID's budget, more than $2.2 billion, was devoted to biodefense research programs, which the Post reported will now be run by the Department of War. Bhattacharya and Powers told the paper they had combed through more than 8,000 research grants to make sure none of the laboratory work involved dangerous experiments of the kind classified as biodefense.
Bhattacharya made no secret of his view of that work. He described biodefense research as going out to find emerging diseases in remote places, bringing them into laboratories and making them more transmissible and better able to infect humans, then developing what he called "poorly tested countermeasures." The civilian justifications offered for it were far-fetched, he said, given that potential pathogens number "literally in the trillions." "We're out of that business altogether," he said.
Powers is a physician-scientist who has worked with NIAID since 1999 in roles focused on clinical research. The institute's official biography identifies him as its deputy director and an attending physician in infectious diseases at the NIH Clinical Center, and notes earlier service at the Food and Drug Administration as lead medical officer for antimicrobial drug development and resistance initiatives. He has written more than 150 peer-reviewed scientific publications and book chapters and co-chaired the U.S. Inter-agency Task Force on Antimicrobial Resistance, the biography says.
In the Post interview, Powers recalled his early years as a clinician, when "HIV patients were dying," and contrasted that era with today, when patients can be sent home on one pill a day. The institute is now putting far more emphasis on implementation research, he said, meaning work to get interventions to the people who need them. He also said NIAID would move away from "setting policy," another point of contention during the pandemic. "Our job is not to tell everybody what to do," Powers said. "Our job is to provide them with the information to make the best decisions." As a practicing physician, he added, he sees unanswered questions about measures such as masks, and the institute's role is to support the research that could resolve them.
The appointment follows a turbulent stretch. The administration ousted Jeanne Marrazzo in March 2025, and Jeffery Taubenberger, who was then named acting director, unexpectedly stepped down; several other NIAID leaders were reassigned to other institutes or asked to resign. Bloomberg Law described the post as one of the most critical health positions not permanently filled over the past year. NIAID is the second-largest component of the NIH and oversees research into treating and preventing illnesses including COVID-19, influenza, Ebola and HIV/AIDS.
Powers inherits an institute that Anthony Fauci led for nearly four decades, and the dispute over its pandemic-era grants continues. Fauci has repeatedly denied in congressional testimony that the institute funded gain-of-function experiments at the Wuhan Institute of Virology, the Post noted, while Bhattacharya and other scientists have disputed that account or said it is impossible to know what Chinese researchers studied under the U.S.-funded grant. STAT's report on the appointment described as unsubstantiated the accusations that research funded by the institute in China played a role in creating the virus that causes COVID-19. Bhattacharya, for his part, told the Post that Fauci's actions were at "the root of a lot of the distrust that Americans have over the NIH."
The administration has also come under fire for broad cuts to medical research at the NIH, Bloomberg Law noted in its coverage of the appointment. Bhattacharya said the agency has been working closely with Congress to deliver records from the pandemic era.